Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) most commonly causes a mild respiratory illness; however, there are wide ranges of presenting symptoms and disease severity. It has a mortality rate around 7%. We present a case of a 9-year-old female patient with hypoplastic left heart syndrome status post heart transplantation at age of 7 days. She presented to our emergency room complaining of intermittent fever, chills, fatigue, poor appetite, and diarrhea. A throat swab nucleic acid test was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intravenous fluids therapy was used for correction of hydration status. To the best of our knowledge this is the first reported case of non-pulmonary presentation of coronavirus disease-2019 (COVID-19) in a pediatric heart transplant recipient, which was successfully managed conservatively. Gastrointestinal manifestations can be the only presenting symptom in pediatric heart transplant recipients with COVID-19. Conservative treatment could be used successfully. Immunomodulatory medications that are used in heart transplant recipients may have protective value in SARS-CoV-2 infection.

中文翻译：

---

儿科心脏移植受者中COVID-19的胃肠道表现

严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）相关的冠状病毒病2019（COVID-19）最常引起轻度呼吸道疾病; 但是，呈现症状和疾病严重程度的范围很广。它的死亡率约为7％。我们介绍了一名9岁女性患者，该患者在7天大的心脏移植后患有发育不良的左心综合征。她出现在我们急诊室，抱怨间歇性发烧，发冷，疲倦，食欲不振和腹泻。严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）的咽拭子核酸测试呈阳性。静脉输液疗法用于纠正水合状态。据我们所知，这是第一例在小儿心脏移植受者中报告的2019年非肺部冠状病毒病（COVID-19）病例，已成功保守治疗。胃肠道表现可能是COVID-19的小儿心脏移植受者中唯一出现的症状。保守治疗可以成功使用。用于心脏移植受者的免疫调节药物可能对SARS-CoV-2感染具有保护价值。